7 Biotech Stocks With Big Upcoming Catalysts

Are you ready?

Portrait of young Middle-Eastern scientist looking in microscope while working on medical research in science laboratory, copy space
(Image credit: Getty Images)

Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing.

Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment.

Of course, the opposite can also be true – prices can fall just as quickly if data or approvals fail to impress. That’s why it’s so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a “Moderate Buy” or “Strong Buy”) and the expected upside potential based on recent ratings.

Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We’ll also explore the pros’ analysis and price targets for each company.

Data is as of Aug. 7, 2018.

Harriet Lefton
Contributing Writer, Kiplinger.com
Harriet Lefton, originally from the U.K., began her career as a journalist specializing in the niche world of metal markets. She graduated from the University of Cambridge before becoming a qualified U.K. lawyer. Now she has turned her attention to the world of financial blogging, covering U.S. stocks, analysts and all manner of things finance-related.